+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ophthalmology Drugs Market Global Briefing 2018

  • ID: 4452384
  • Report
  • January 2018
  • Region: Global
  • 34 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Allergan Plc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Gilead
  • Novartis AG
  • Shire Plc
  • MORE
North America was the largest region in the ophthalmology drugs market in 2017, accounting for around 30% market share. This was mainly due to the high per capita healthcare expenditure and access to advanced eye care facilities in the region. Western Europe was the second largest region accounting for around 22% market share. Africa was the smallest region accounting for around 3% market share.

Opthalmalogy Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global opthalmalogy drugs sector.

Reasons to Purchase:
  • Fully updated for 2018.
  • Identify growth segments and opportunities.
  • Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
  • Develop strategies based on likely future developments.
  • Gain a global perspective on the development of the market.
Description

Opthalmalogy Market Global Briefing 2018 covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the opthalmalogy drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the opthalmalogy drugs market and suggests approaches.

Scope:

Markets Covered: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs.
Companies Mentioned: Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc., Valeant Pharmaceuticals Intl Inc., Bayer AG, Santen Pharmaceutical Co., Ltd., Gilead, Otsuka Pharmaceutical Co., Ltd., Shire Plc.
Geographic Scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa
Time Series: Five years historic and forecast.
Data: Market value in $ billions.
Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Gilead
  • Novartis AG
  • Shire Plc
  • MORE
Ophthalmology Drugs Market Characteristics
Ophthalmology Drugs Market Historic Growth (2013 - 2017)
Ophthalmology Drugs Market Forecast Growth (2017 - 2021)
Ophthalmology Drugs Market Segmentation
Global Ophthalmology Drugs Market, Split by Segments, 2017, $ Billion
Other Opthalmological Drugs
Antiglaucoma
Dry Eye Medication
Global Ophthalmology Drugs Market, Historic and Forecast, Split by Segments, 2013 - 2021
Ophthalmology Drugs Market Geography Regional and Country Comparison
Global Ophthalmology Drugs Market, Split by Regions, 2017
Global Ophthalmology Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Global Ophthalmology Drugs Market, Split by Country, 2017
Global Ophthalmology Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Ophthalmology Drugs Market Competitive Landscape
Novartis AG
F. Hoffmann-La Roche Ltd
Allergan Plc
Valeant Pharmaceuticals Intl Inc
Bayer AG
Santen Pharmaceutical Co., Ltd
Gilead
Otsuka Pharmaceutical Co., Ltd
Shire Plc
Novartis AG
F.Hoffmann-La Roche
Allergan
Ophthalmology Drugs Market Key Mergers and Acquisitions
Actavis Plc. Acquired Allergan Inc
Santen Pharmaceutical Acquired Merck’s Ophthalmology Products
Astellas Pharma Acquired Ocata Therapeutics
Horizon Pharma Acquired River Vision Development Corp
Sun Pharma Acquired InSite Vision
Novartis Acquired Encore Vision
Purdue Canada Acquired Merck’s Ophthalmology Portfolio
Lupin Acquired Laboratorios Grin
Ophthalmology Drugs Market Trends and Strategies
Rho-Kinase Inhibitors in Glaucoma Treatment
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) For Dry Eye Treatment
Development of Combination Therapies
Appendix
NAICS Definitions of Industry Covered in This Report
Definition of Market Covered in This Report
Abbreviations
Currencies
Research Methodology
Research Inquiries
About the Publisher

List of Figures
Figure 1: Global Ophthalmology Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Figure 2: Global Ophthalmology Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Figure 3: Global Ophthalmology Drugs Market, Split by Segments, 2017, $ Billion
Figure 4: Global Ophthalmology Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Figure 5: Global Ophthalmology Drugs Market, Split by Region, 2017, $ Billion
Figure 6: Global Ophthalmology Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Figure 7: Global Ophthalmology Drugs Market, Split by Country, 2017, $ Billion
Figure 8: Global Ophthalmology Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Figure 9: Global Ophthalmology Drugs Market, Key Competitor Market Shares, 2017, Percentage (%)

List of Tables
Table 1: Global Ophthalmology Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Table 2: Global Ophthalmology Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Table 3: Global Ophthalmology Drugs Market, Split by Segments, 2017, $ Billion
Table 4: Global Ophthalmology Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Table 5: Global Ophthalmology Drugs Market, Split by Region, 2017, $ Billion
Table 6: Global Ophthalmology Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Table 7: Global Ophthalmology Drugs Market, Split by Country, 2017, $ Billion
Table 8: Global Ophthalmology Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Table 9: Global Ophthalmology Drugs Market, Key Competitor Market Shares, 2017, Percentage (%)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allergan Plc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Gilead
  • Novartis AG
  • Shire Plc
  • MORE
The ophthalmology drugs market covers drugs that are used in the treatment of eye related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and macular degeneration. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax.

North America was the largest region in the ophthalmology drugs market in 2017, accounting for around 30% market share. This was mainly due to the high per capita healthcare expenditure and access to advanced eye care facilities in the region. Western Europe was the second largest region accounting for around 22% market share. Africa was the smallest region accounting for around 3% market share.

Rho-Kinase Inhibitors in Glaucoma Treatment - Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression. These inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition. Major Rho-kinase inhibitors being developed include ATS907, ATS8535, AR-12286, AR-13324, AMA0076 and BOL-303259-X.
Note: Product cover images may vary from those shown
5 of 5
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Allergan Plc.
  • Valeant Pharmaceuticals Intl Inc.
  • Bayer AG
  • Santen Pharmaceutical Co. Ltd.
  • Gilead
  • Otsuka Pharmaceutical Co. Ltd.
  • Shire Plc
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll